Barr's bid for biogenerics line seen as risky by some

09/16/2006 | CNNMoney

Stock analysts are labeling as "risky" the $2.5 billion bid Barr Pharmaceuticals has made for the Croatian Pliva to get access to its biogenerics drug line. Some called the bid by the U.S. generics maker "speculative" for an industry still in early stages of development. Competing bidder Actavis, of Iceland, has until Sept. 27 to top Barr's bid.

View Full Article in:

CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT